Meribank Biotech Co Stock

Meribank Biotech Co Equity

The The Equity of Meribank Biotech Co (4724.TWO) as of Aug 26, 2026 is 1.25 B TWD. In the previous year, The Equity was 1.21 B TWD — a change of 3.60% (higher).

Equity

1.25 BTWD

YoY

3.60%

Last updated:

In 2026, Meribank Biotech Co's equity was 1.25 B TWD, a 3.60% increase from the 1.21 B TWD equity in the previous year.

The Meribank Biotech Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
434.36 M TWD
Jan 1, 2020
382.64 M TWD
Jan 1, 2021
586.05 M TWD
Jan 1, 2022
471.20 M TWD
Jan 1, 2023
661.73 M TWD
Jan 1, 2024
1.21 B TWD
Jan 1, 2025
1.25 B TWD
The Meribank Biotech Co Equity history
YEAREquityYoY
1.25 BTWD+3.60%
1.21 BTWD+82.21%
661.73 MTWD+40.43%
471.20 MTWD-19.60%
586.05 MTWD+53.16%
382.64 MTWD-11.91%
434.36 MTWD—
Access this data via the Eulerpool API
Get Free API Key

Meribank Biotech Co Stock analysis

What does Meribank Biotech Co do? Meribank Biotech Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Meribank Biotech Co's Equity

Meribank Biotech Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Meribank Biotech Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Meribank Biotech Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Meribank Biotech Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Meribank Biotech Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Meribank Biotech Co stock

The Equity of Meribank Biotech Co is 1.25 B TWD in 2026.

The Equity of Meribank Biotech Co changed from 1.21 B TWD to 1.25 B TWD, representing a 3.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Meribank Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Meribank Biotech Co historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Meribank Biotech Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Meribank Biotech Co